Page 59 - 南京医科大学自然版
P. 59

第45卷第7期          李国花,蔡文玉,张登庆,等. 血色素结合蛋白与载脂蛋白B乘积对冠心病诊断价值的临床
                  2025年7月                研究[J]. 南京医科大学学报(自然科学版),2025,45(7):954-962,972                  ·957 ·


               (续表1)
                             Characteristic               CAD(n=107)              Control(n=33)           P
                   Cr[μmol/L,M(P25,P75 )]               79.30(66.87,95.58)      68.31(55.40,84.74)       0.006
                   eGFR[mL/(min·1.73 m),M(P25,P75 )]   86.50(71.00,103.00)      95.00(79.00,107.50)      0.078
                                     2
                   lg(Hpx)[M(P25,P75 )]                  2.79(2.57,3.54)          2.73(2.50,3.28)        0.262
                   Hpx>P75 [n(%)]                           32(29.90)               4(12.12)             0.041
                   Hpx·apoB[mg /L ,M(P25,P75 )]          2.23(1.71,2.98)          1.68(1.27,2.31)        0.005
                              2
                                2
                   Antiplatelet drugs[n(%)]                104(97.20)               17(51.52)          < 0.001
                   Beta⁃blockers[n(%)]                      24(22.40)               11(33.30)            0.206
                   Statins[n(%)]                            54(50.50)               17(51.50)            0.916
                   ACEI/ARB[n(%)]                           66(61.70)               17(51.50)            0.299
                   Insulin[n(%)]                            9(8.40)                  2(6.10)             0.661
                   LVEF[%,M(P25,P75 )]                  61.00(56.00,65.08)      62.70(60.00,67.45)       0.046

                   Drug utilization data were collected from medication records documented at the time of hospital admission. SBP:systolic blood pressure;DBP:
                diastolic blood pressure;WBC:white blood cell count;Hb:hemoglobin;TG:triglycerides;TC:total cholesterol;HDL⁃C:high⁃density lipoprotein
                cholesterol;N⁃HDL⁃C:non⁃high⁃density lipoprotein cholesterol;FBG:fasting blood glucose;BUN:blood urea nitrogen;eGFR:estimated glomerular
                filtration rate;lg(Hpx):the common logarithm of hemopexin value;Hpx>P75:hemopexin protein concentration in the upper quartile;ACEI/ARB:
                angiotensin⁃converting enzyme inhibitors/angiotensin receptor blockers;LVEF:left ventricular ejection fraction.
                2.2  Hpx·apoB及其他相关指标在CAD不同临床亚                     表 3);冠状动脉多支病变组和单支病变组显著高
                型中的比较                                             于 对 照 组(P=0.002,表 4)。 此 外 ,CRP、proBNP、
                    进一步对不同分组间Hpx·apoB水平进行比较,                      TnT、Cr 在急性冠脉综合征组(表 2)、急性心肌梗
                发现急性冠脉综合征组 Hpx·apoB 水平显著高于慢                       死组(表 3)及冠脉多支病变组(表 4)中均显著升
                性稳定性CAD组和对照组(P < 0.001,表2);急性心                    高(P 均 < 0.05),低密度脂蛋白胆固醇(low⁃density
                梗组显著高于稳定性 CAD 组(P=0.003);急性心梗                     lipoprotein cholesterol,LDL⁃C)在冠脉多支病变组与
                组、不稳定型心绞痛组显著高于对照组(P < 0.001,                      单支病变组间差异无统计学意义(P > 0.05)。
                             表2 Hpx·apoB及其他相关指标在急性冠脉综合征、慢性稳定性冠心病与对照组间的比较
                Table 2  Comparison of Hpx·apoB and other indicators among acute coronary syndrome,chronic coronary syndrome and
                       control groups                                                               [M(P25,P75 )]
                    Indicator    Acute coronary syndrome(n=78)  Chronic coronary syndrome(n=29)  Control(n=33)  P
                 Hpx·apoB(mg /L)       2.36(1.86,3.13)            1.72(1.29,2.44)        1.68(1.27,2.31)  < 0.001
                           2
                             2
                 CRP(mg/L)            4.29(1.10,15.40)            1.35(0.70,4.45)        1.40(0.75,2.51)   0.005
                 proBNP(ng/L)      466.00(121.00,1 206.50)      110.82(36.70,235.40)   85.56(44.39,163.00)  < 0.001
                 TnT(μg/L)          151.50(13.74,1 825.50)       13.60(9.45,20.90)      7.66(6.32,11.18)  < 0.001
                 LDL⁃C(mmol/L)         3.12(2.36,3.77)            2.17(1.86,3.08)        2.63(1.99,3.32)   0.008
                 Cr(μmol/L)          83.12(67.72,101.41)        73.60(63.65,84.04)      68.31(55.54,84.74)  0.006

                       表3   Hpx·apoB及其他相关指标在急性心肌梗死、不稳定型心绞痛、慢性稳定性冠心病与对照组间的比较
                  Table 3  Comparison of Hpx·apoB and other indicators among acute myocardial infarction,unstable angina,chronic
                          coronary syndrome and control groups                                      [M(P25,P75 )]

                                   Acute myocardial    Unstable angina  Chronic coronary
                    Indicator                                                              Control(n=33)     P
                                   infarction(n=55)      (n=23)         syndrome(n=29)
                Hpx·apoB(mg /L)    2.37(1.88,3.23)    2.35(1.78,2.95)   1.72(1.29,2.44)   1.68(1.27,2.31)  < 0.001
                           2
                             2
                CRP(mg/L)          8.30(1.95,21.94)   1.10(0.50,2.12)   1.34(0.70,4.45)   1.40(0.75,2.51)  < 0.001
                proBNP(ng/L)    737.50(266.85,2 095.00) 99.80(38.50,460.80) 110.82(36.70,235.40) 85.56(44.39,163.00)  < 0.001
                TnT(μg/L)       876.00(110.00,2 682.00)  12.66(8.86,35.40)  13.60(9.45,20.90)  7.66(6.32,11.18)  < 0.001
                LDL⁃C(mmol/L)      3.23(2.64,3.91)    2.52(2.05,3.55)   2.17(1.86,3.08)   2.63(1.99,3.32)   0.004
                Cr(μmol/L)       82.85(68.94,100.48)  87.62(66.87,103.33)  73.60(63.65,84.04)  68.31(55.54,84.74)  0.016
   54   55   56   57   58   59   60   61   62   63   64